GENE EDITING 101
All Companies
🇨🇳

HuidaGene Therapeutics

Private

Next-gen CRISPR for neurological diseases

HuidaGene is a clinical-stage Chinese biotech developing next-generation gene editing therapies using its proprietary Cas12i and Cas13Y systems. The company focuses on neurological diseases including ALS and Duchenne muscular dystrophy, with AI-driven CRISPR tool development.

Founded2018
HQShanghai, China
CEOChen Yong
StatusPrivate
Total Funding$150M

Pipeline

Drug / ProgramIndicationPhaseTechnology
HG-DMDDuchenne Muscular DystrophyPhase 1CRISPR-Cas12i
HG-ALSALSPreclinicalCRISPR-Cas12i
HG-MECP2MECP2 Duplication SyndromePreclinicalCas13Y RNA editing

Key People

Chen YongCEO & Co-founder

Related Articles

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?
Biotech Companies
Market Analysis

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?

A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.

Mar 16, 20266 min read